中国当代医药
中国当代医药杂志欢迎您 今天是   2025年1月13日星期一
设为首页  加入收藏  联系我们         
 
      首 页    |    本刊简介     |    期刊荣誉     |    编采团队     |    会务培训     |    理事单位     |    下载专区     |    在线留言     |    联系我们     |     返回中国当代医药网
中国当代医药  2022, Vol. 29 Issue (13): 51-53    
  神经与精神疾病 本期目录 | 过刊浏览 | 高级检索 |
阿加曲班辅助治疗在伴有早期神经功能恶化的急性缺血性脑卒中患者中的应用
徐 庶 张雯君
江苏省张家港市第一人民医院神经内科,江苏张家港 215600
Application of Argatroban adjuvant therapy in acute ischemic stroke patients with early deterioration of neurological function
XU Shu ZHANG Wenjun
Department of Neurology,the First People′s Hospital of Zhangjiagang City,Jiangsu Province,Zhangjiagang 215600,China
全文: PDF (552 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 探讨阿加曲班辅助治疗在伴有早期神经功能恶化的急性缺血性脑卒中患者中的应用效果。方法 选取2018年6月至2021年6月张家港市第一人民医院收治的160 例急性缺血性脑卒中患者作为研究对象, 采用随机摸球法将其分为A 组与B 组,每组各80 例。B 组患者采用阿司匹林治疗,A 组患者加用阿加曲班辅助治疗。比较两组患者的脑神经功能缺损程度、纤维蛋白原(FIB)、神经肽(NPY)水平。结果 两组患者治疗后的改良爱丁堡-斯堪的那维亚神经功能缺损评分量表(MIESSS)评分低于治疗前,且A 组患者治疗后的MIESSS 评分低于B 组,差异有统计学意义(P<0.05)。 两组患者治疗后的FIB、NPY 水平低于治疗前,且A 组患者治疗后的FIB、NPY 水平低于B 组,差异有统计学意义(P<0.05)。 结论 伴有早期神经功能恶化的急性缺血性脑卒中患者给予阿加曲班辅助治疗,对脑神经功能缺损程度有显著降低作用,可调节FIB、NPY 水平。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 阿加曲班早期神经功能恶化急性缺血性脑卒中临床疗效纤维蛋白原神经肽    
Abstract:Objective To investigate the effect of Agattroban adjuvant therapy in acute ischemic stroke patients with early neurological deterioration. Methods A total of 160 patients with acute ischemic stroke admitted to the First People′s Hospital of Zhangjiagang City from June 2018 to June 2021 were selected as the study subjects. They were divided into group A and group B by random touch ball method, with 80 cases in each group. Patients in group B were treated with Aspirin, and patients in group A were treated with Agattroban. The degree of cerebral nerve function defect, the level of fibrinogen (FIB) and neuropeptide (NPY) in the two groups were compared. Results The modified Edinburgh-Scandinavian neurological impairment score scale (MIESSS) scores of the two groups after treatment were lower than those before treatment, and the MIESSS score of group A was lower than that in the group B, the differences were statistically significant (P<0.05). After treatment, FIB and NPY levels in the two groups were lower than those before treatment, and FIB and NPY levels in group A were lower than those in group B, the differences were statistically significant (P<0.05). Conclusion In acute ischemic stroke patients with early neurological deterioration, adjunctive treatment with Agattroban can significantly reduce the degree of cerebral neurological impairment and regulate the level of FIB and NPY.
Key wordsAgatuban    Early neurological deterioration    Acute ischemic stroke    Clinical efficacy    Fibrinogen    Neuropeptide
    
基金资助:江苏省张家港市卫计系统青年科技项目(ZJGQN KJ201805)
作者简介: 徐庶(1983-),男,江苏阜宁人,硕士,副主任医师,研究方向:脑血管病、帕金森病。
引用本文:   
徐庶; 张雯君. 阿加曲班辅助治疗在伴有早期神经功能恶化的急性缺血性脑卒中患者中的应用[J]. 中国当代医药, 2022, 29(13): 51-53.
XU Shu ZHANG Wenjun. Application of Argatroban adjuvant therapy in acute ischemic stroke patients with early deterioration of neurological function. 中国当代医药, 2022, 29(13): 51-53.
链接本文:  
https://www.dangdaiyiyao.com/CN/     或     https://www.dangdaiyiyao.com/CN/Y2022/V29/I13/51
中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP备11001767号-6  京公网安备 11010502046607号  互联网药品信息服务资格证  期刊出版许可证  广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626690 总机:010-59626692/18/19/20   传真:010-59626204   投稿信箱:ddyy@vip.163.com
地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室   邮编:100124
技术支持:北京玛格泰克科技发展有限公司
Copyright 2000-2014 版权所有 《中国当代医药》杂志社 未经授权请勿转载